Aurobindo Pharma Reports Q4 FY26 Results; Confirms Auditor Changes and Shares Data
Aurobindo Pharma Limited announced key corporate updates and released its financial results for the fiscal year ending March 31, 2026. The Board of Directors also approved the reappointment of various auditors and detailed the company’s strategic activities, including a major business transfer and share buyback.Financial Performance Overview (Year Ended March 31, 2026)
The company released comprehensive statements detailing both standalone and consolidated financial results.Consolidated Financial Highlights:
The consolidated results for the year ended March 31, 2026, showed substantial growth across key financial metrics.
| Particulars | Year ended March 31, 2026 | Year ended March 31, 2025 |
|---|---|---|
| Total revenue from operations | 3,36,530.8 million | 3,17,237.3 million |
| Total income (1+2) | 3,41,451.7 million | 3,23,455.8 million |
| Total expenses | 2,89,695.1 million | 2,72,476.0 million |
| Profit before tax | 51,118.5 million | 50,662.9 million |
| Profit after tax | 35,029.7 million | 34,835.7 million |
| Total comprehensive income (net of tax) | 19,652.0 million | 3,036.2 million |
Standalone Financial Highlights:
The standalone financials for the year ended March 31, 2026, reported a total revenue from operations of 1,11,717.2 million, up from 1,09,333.0 million in the previous fiscal year. The Profit after Tax stood at 24,148.0 million.
| Financial Metric (Standalone) | Year ended March 31, 2026 | Year ended March 31, 2025 |
|---|---|---|
| Total revenue from operations | 1,11,717.2 million | 1,09,333.0 million |
| Total income (1+2) | 1,17,592.5 million | 1,12,614.2 million |
| Profit after tax | 24,148.0 million | 17,467.9 million |
***
Corporate Governance and Appointments
The Board meeting held on May 21, 2026, addressed several corporate appointments:- Secretarial Auditor: M/s. MRR & Associates resigned as Secretarial Auditors effective May 22, 2026, citing health issues of its sole proprietor. The Board approved the appointment of M/s. RPR & Associates, Company Secretaries in Practice, as the new Secretarial Auditors for a term of five consecutive years, beginning from FY 2026-27, subject to shareholder approval at the Annual General Meeting.
- Internal Auditor: M/s. Ernst & Young LLP (EY) were re-appointed as Internal Auditors for the period from June 2026 to May 2027.
Major Corporate Actions
Business Transfer:The Board of Directors approved the transfer of the domestic branded generic pharmaceutical formulations business. This transfer, structured as a slump sale, is moving the business to Auropharm Limited, a wholly owned subsidiary, effective April 1, 2026.
Share Buyback:
The company's board previously approved the buyback of 5,423,728 fully paid-up equity shares (face value of 1 each). The buyback was executed in a tender offer route, resulting in the acceptance of 5,423,728 equity shares and the payment of consideration totaling 8,000.0 million to eligible shareholders on May 7, 2026.
Subsidiaries and Associates Details
The Group's global structure includes a wide network of subsidiaries and joint ventures across multiple countries. Key component entities reported in the consolidated financial results include:| Component Entity | Country | Relationship |
|---|---|---|
| Helix Healthcare B.V. | The Netherlands | Direct Subsidiary |
| Aurobindo Pharma USA Inc. | USA | Direct Subsidiary |
| Aurobindo Pharma Limited | India | Direct Subsidiary |
| Agile Pharma B.V. | The Netherlands | Step-Down Subsidiary |
| Aurobindo Pharma (Malaysia) SDN. BHD. | Malaysia | Step-Down Subsidiary |
| Engenra Biologics Private Limited | India | Direct Subsidiary / Joint Venture |
The company also maintains a significant portfolio of international operations, with over 90 listed subsidiaries and associates spanning countries including the Netherlands, Brazil, USA, India, and various European nations.
AUROPHARMA Stock Price Movement
Aurobindo Pharma Limited shares today edged higher, settling at ₹1546.7, marking a 2.11% gain. The stock rallied amid 1.01 million shares traded, notably touching its 52-week high of ₹1550.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: